Siyuan Cheng
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
Publications
32
Citations
251
Est. group size
~7
Recurring co-author estimate
Active years
14
Publishing since 2012
This researcher's publication record centers on cancer biology, particularly the molecular drivers of prostate cancer progression (such as PROX1, Stathmin 1, and neuroendocrine differentiation markers like INSM1), as well as gastric and gastrointestinal cancers, including how gut microbiome composition relates to response to immunotherapy. Some listed publications also touch on unrelated topics like machine learning benchmarks and protein knowledge graphs, suggesting the bibliographic record may include contributions from shared-name authors or collaborative side projects. Prospective students interested in cancer molecular biology, tumor microenvironment, or microbiome-immunotherapy interactions may find this body of work relevant.
Publication output was minimal or absent before 2022, then rose sharply in 2023 with a slight decline through 2024-2025, indicating a recent surge in research activity rather than a long, steady decade-long trend.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- PROX1 is an early driver of lineage plasticity in prostate cancer
Journal of Clinical Investigation · 2025
- Stathmin 1 expression in neuroendocrine and proliferating prostate cancer
Discover Oncology · 2025
- Deep learning-driven multidistance imaging metasurface
2025
- ChineseHarm-Bench: A Chinese Harmful Content Detection Benchmark
arXiv (Cornell University) · 2025
- Regulation of INSM1 Gene Expression and Neuroendocrine Differentiation in High-Risk Neuroblastoma
Biology · 2025
- Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data
Signal Transduction and Targeted Therapy · 2024
- Multi-omics of the gut microbial ecosystem in patients with microsatellite-instability-high gastrointestinal cancer resistant to immunotherapy
Cell Reports Medicine · 2024
- Stathmin 1 Expression in Neuroendocrine and Proliferating Prostate Cancer
Research Square · 2024
- Hepatic IDH2 regulates glycolysis and gluconeogenesis
Metabolism · 2023
- Data from The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer
2023
- Multi-omics of the gut microbial ecosystem in the immunotherapy resistance in microsatellite instability-high gastrointestinal cancer patients
bioRxiv (Cold Spring Harbor Laboratory) · 2023
- Data from The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer
2023
- Abstract 1446: The elevated expression of INSM1 is correlated with EZH2 in neuroendocrine prostate cancer
Cancer Research · 2023
- Supplementary Figures from The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer
2023
- Supplementary Tables from The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer
2023
- arXiv (Cornell University)×4
- Signal Transduction and Targeted Therapy×1
- Cell Reports Medicine×1
- Metabolism×1
- Journal of Clinical Investigation×1
- Andrea R. Merchak
Biochemistry, Genetics and Molecular Biology · Indiana University
- Andrew Gold
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Amna Bibi
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Amy R. Mackos
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Anice Sabag-Daigle
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile